Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L...
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics ...
Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting...
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO,...
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial...
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca (ERAS) has surged 460% over the past year, driven by strong technical momentum. ERAS hit a new 3-year high of $10.92 on Monday. Despite bullish technicals, ERAS has no revenue, is burning cash,...
SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...